| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3984811 | European Journal of Surgical Oncology (EJSO) | 2015 | 4 Pages |
ObjectiveEpidemiological studies on aspirin and stomach cancer have been inconclusive. The purpose of our study was to investigate the association between aspirin and stomach cancer in China.MethodA 1:2 matched case–control study was conducted in four large medical centers. A self-designed questionnaire was used to collect information. Unconditional logistic regression was used to compute crude and adjusted odds ratios (ORs) with 95% confidence intervals (CIs).ResultOur study indicated that risk of stomach cancer was greatly reduced for regular aspirin user (OR = 0.62; 95% CI 0.42–0.80). Specifically, dosage and tablet-years of use were associated with lower risk (OR = 0.54; 95% CI 0.29–0.84 for ≥7 tabs/week; OR = 0.47; 95% CI 0.32–0.81 for ≥10 tablet years, respectively). Furthermore, the finding was strengthened by stratified studies of gender, smoking status, body mass index (BMI) and helicobacter pylori.ConclusionOur study confirmed that regular aspirin use is a protective factor to stomach cancer.
